オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - alpha-cypermethrin - topical solution/suspension - alpha-cypermethrin pyrethroid active 50.0 g/l - parasiticides - lamb | sheep | sheep long wool (unshorn) | ewe | hogget | lamb | ovine | ram | unshorn | weaner | wether - fly strike | sheep body louse | blowfly strike | body & crutch strike | body strike only | crutch strike | damalinia ovis (prev. genus) | lice - synthetic pyrethroid re | poll strike | sheep body lice

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - alpha-cypermethrin - suspension concentrate - alpha-cypermethrin pyrethroid active 250.0 g/l - insecticide

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ezycrop pty ltd - alpha-cypermethrin; liquid hydrocarbon - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; liquid hydrocarbon solvent other 735.0 g/l - insecticide

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elders rural services australia limited - alpha-cypermethrin; hydrocarbon liquid - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; hydrocarbon liquid solvent other 760.0 g/l - insecticide

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1 g in 50 ml - glassia is an alpha1 -proteinase inhibitor (human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of alpha1 -pi, also known as alpha1 -antitrypsin (aat) deficiency. limitations of use : - the effect of augmentation therapy with glassia or any alpha1 -pi product on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with glassia are not available. - glassia is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. glassia is contraindicated in: - immunoglobulin a (iga) deficient patients with antibodies against iga. - individuals with a history of anaphylaxis or other severe systemic reaction to alpha1 -pi products. risk summar

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - alpha tocopheryl acetate - oral suspension - 100mg/1ml

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin® -c liquid is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c liquid, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.    - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c liquid are not available. - prolastin-c liquid is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c liquid is contraindicated in: - iga deficient patients with antibodies against iga, due to the risk of severe hypersensitivity. - patients with a history of anaphylaxis or other sever

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

melrose laboratories pty ltd - evening primrose oil, quantity: 886.0523 mg/ml (equivalent: gamma-linolenic acid, qty 88.6 mg/ml) - liquid, multipurpose - excipient ingredients: mixed (low-alpha type) tocopherols concentrate; thaumatin; flavour - maintain/support general health and wellbeing ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support female healthy hormonal balance ; helps reduce occurrence of premenstrual tension symptoms ; decrease/reduce/relieve skin peeling/cracking ; helps reduce occurrence of skin dryness ; maintain/support skin firmness ; maintain/support skin health ; maintain/support skin integrity/structure

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxycillin trihydrate -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride -